C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel
Objective/Background: Chimeric antigen receptor (CAR) T-cell is an effective therapy in relapsed/refractory large B-cell lymphomas that, due to its unique toxicities, often requires escalation of care to the intensive care unit (ICU) setting. C-reactive protein (CRP) and ferritin are serum inflammat...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-06-01
|
Series: | Hematology/Oncology and Stem Cell Therapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1658387620301515 |
id |
doaj-844ab7651846403fbcc18b946b082f45 |
---|---|
record_format |
Article |
spelling |
doaj-844ab7651846403fbcc18b946b082f452021-05-22T04:36:21ZengElsevierHematology/Oncology and Stem Cell Therapy1658-38762021-06-01142141146C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucelMegan Melody0Zaid Abdel Rahman1Hollie Saunders2Paula Lengerke Diaz3Nicole Gannon4Allison Rosenthal5Ernesto Ayala6Han W. Tun7Hemant Murthy8Vivek Roy9James Foran10Januario E. Castro11Pramod Guru12Mohamed A. Kharfan-Dabaja13Department of Internal Medicine, Mayo Clinic, Jacksonville, FL, USADivision of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USADepartment of Internal Medicine, Mayo Clinic, Jacksonville, FL, USADivision of Hematology-Oncology and Blood and Marrow Transplantation, Mayo Clinic, Phoenix, AZ, USADivision of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USADivision of Hematology-Oncology and Blood and Marrow Transplantation, Mayo Clinic, Phoenix, AZ, USADivision of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USADivision of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USADivision of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USADivision of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USADivision of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USADivision of Hematology-Oncology and Blood and Marrow Transplantation, Mayo Clinic, Phoenix, AZ, USADepartment of Critical Care Medicine, Mayo Clinic, Jacksonville, FL, USADivision of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA; Corresponding author at: Mayo Clinic, 4500 San Pablo Rd S, Mangurian Building, 3rd Floor, Jacksonville, FL 32224, USA.Objective/Background: Chimeric antigen receptor (CAR) T-cell is an effective therapy in relapsed/refractory large B-cell lymphomas that, due to its unique toxicities, often requires escalation of care to the intensive care unit (ICU) setting. C-reactive protein (CRP) and ferritin are serum inflammatory markers associated with onset and persistence of CAR T-cell-related toxicity. Methods: We retrospectively analyzed 34 patients treated with axicabtagene ciloleucel (axi-cel) who were divided into two groups: patients requiring admission to the ICU during initial hospitalization (n = 13, 38%) and those who did not (n = 21, 62%). Primary objective was to examine possible relationships between serum ferritin and/or CRP levels with the need for, and length of, ICU stay between these groups. Results: All 13 patients admitted to the ICU developed cytokine release syndrome (CRS) and 11 of them also developed neurotoxicity (NT). Of the 21 patients in the non-ICU group, 18 developed CRS and 5 patients developed NT. Grade of CRS and NT were higher in ICU versus non-ICU patients (p = .03 and .001, respectively). There was no correlation between CRP levels at time of ICU admission and length of ICU stay (correlation of 0.41, p = .17). Yet, there was an association between serum ferritin levels and length of ICU stay (R2 = 0.73) which did not reach statistical significance (correlation of 0.21, p = .49). Conclusion: Notwithstanding the limitations of the small sample size, our study suggests that an elevated ferritin level at the time of escalation of medical care may be possibly indicative of anticipated prolonged ICU hospitalization in patients treated with axi-cel. A large multicenter study is certainly needed to confirm this observation.http://www.sciencedirect.com/science/article/pii/S1658387620301515Axicabtagene ciloleucelCAR T cellCRPDLBCLFerritin |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Megan Melody Zaid Abdel Rahman Hollie Saunders Paula Lengerke Diaz Nicole Gannon Allison Rosenthal Ernesto Ayala Han W. Tun Hemant Murthy Vivek Roy James Foran Januario E. Castro Pramod Guru Mohamed A. Kharfan-Dabaja |
spellingShingle |
Megan Melody Zaid Abdel Rahman Hollie Saunders Paula Lengerke Diaz Nicole Gannon Allison Rosenthal Ernesto Ayala Han W. Tun Hemant Murthy Vivek Roy James Foran Januario E. Castro Pramod Guru Mohamed A. Kharfan-Dabaja C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel Hematology/Oncology and Stem Cell Therapy Axicabtagene ciloleucel CAR T cell CRP DLBCL Ferritin |
author_facet |
Megan Melody Zaid Abdel Rahman Hollie Saunders Paula Lengerke Diaz Nicole Gannon Allison Rosenthal Ernesto Ayala Han W. Tun Hemant Murthy Vivek Roy James Foran Januario E. Castro Pramod Guru Mohamed A. Kharfan-Dabaja |
author_sort |
Megan Melody |
title |
C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel |
title_short |
C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel |
title_full |
C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel |
title_fullStr |
C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel |
title_full_unstemmed |
C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel |
title_sort |
c-reactive protein and ferritin levels and length of intensive care unit stay in patients with b-cell lymphomas treated with axicabtagene ciloleucel |
publisher |
Elsevier |
series |
Hematology/Oncology and Stem Cell Therapy |
issn |
1658-3876 |
publishDate |
2021-06-01 |
description |
Objective/Background: Chimeric antigen receptor (CAR) T-cell is an effective therapy in relapsed/refractory large B-cell lymphomas that, due to its unique toxicities, often requires escalation of care to the intensive care unit (ICU) setting. C-reactive protein (CRP) and ferritin are serum inflammatory markers associated with onset and persistence of CAR T-cell-related toxicity. Methods: We retrospectively analyzed 34 patients treated with axicabtagene ciloleucel (axi-cel) who were divided into two groups: patients requiring admission to the ICU during initial hospitalization (n = 13, 38%) and those who did not (n = 21, 62%). Primary objective was to examine possible relationships between serum ferritin and/or CRP levels with the need for, and length of, ICU stay between these groups. Results: All 13 patients admitted to the ICU developed cytokine release syndrome (CRS) and 11 of them also developed neurotoxicity (NT). Of the 21 patients in the non-ICU group, 18 developed CRS and 5 patients developed NT. Grade of CRS and NT were higher in ICU versus non-ICU patients (p = .03 and .001, respectively). There was no correlation between CRP levels at time of ICU admission and length of ICU stay (correlation of 0.41, p = .17). Yet, there was an association between serum ferritin levels and length of ICU stay (R2 = 0.73) which did not reach statistical significance (correlation of 0.21, p = .49). Conclusion: Notwithstanding the limitations of the small sample size, our study suggests that an elevated ferritin level at the time of escalation of medical care may be possibly indicative of anticipated prolonged ICU hospitalization in patients treated with axi-cel. A large multicenter study is certainly needed to confirm this observation. |
topic |
Axicabtagene ciloleucel CAR T cell CRP DLBCL Ferritin |
url |
http://www.sciencedirect.com/science/article/pii/S1658387620301515 |
work_keys_str_mv |
AT meganmelody creactiveproteinandferritinlevelsandlengthofintensivecareunitstayinpatientswithbcelllymphomastreatedwithaxicabtageneciloleucel AT zaidabdelrahman creactiveproteinandferritinlevelsandlengthofintensivecareunitstayinpatientswithbcelllymphomastreatedwithaxicabtageneciloleucel AT holliesaunders creactiveproteinandferritinlevelsandlengthofintensivecareunitstayinpatientswithbcelllymphomastreatedwithaxicabtageneciloleucel AT paulalengerkediaz creactiveproteinandferritinlevelsandlengthofintensivecareunitstayinpatientswithbcelllymphomastreatedwithaxicabtageneciloleucel AT nicolegannon creactiveproteinandferritinlevelsandlengthofintensivecareunitstayinpatientswithbcelllymphomastreatedwithaxicabtageneciloleucel AT allisonrosenthal creactiveproteinandferritinlevelsandlengthofintensivecareunitstayinpatientswithbcelllymphomastreatedwithaxicabtageneciloleucel AT ernestoayala creactiveproteinandferritinlevelsandlengthofintensivecareunitstayinpatientswithbcelllymphomastreatedwithaxicabtageneciloleucel AT hanwtun creactiveproteinandferritinlevelsandlengthofintensivecareunitstayinpatientswithbcelllymphomastreatedwithaxicabtageneciloleucel AT hemantmurthy creactiveproteinandferritinlevelsandlengthofintensivecareunitstayinpatientswithbcelllymphomastreatedwithaxicabtageneciloleucel AT vivekroy creactiveproteinandferritinlevelsandlengthofintensivecareunitstayinpatientswithbcelllymphomastreatedwithaxicabtageneciloleucel AT jamesforan creactiveproteinandferritinlevelsandlengthofintensivecareunitstayinpatientswithbcelllymphomastreatedwithaxicabtageneciloleucel AT januarioecastro creactiveproteinandferritinlevelsandlengthofintensivecareunitstayinpatientswithbcelllymphomastreatedwithaxicabtageneciloleucel AT pramodguru creactiveproteinandferritinlevelsandlengthofintensivecareunitstayinpatientswithbcelllymphomastreatedwithaxicabtageneciloleucel AT mohamedakharfandabaja creactiveproteinandferritinlevelsandlengthofintensivecareunitstayinpatientswithbcelllymphomastreatedwithaxicabtageneciloleucel |
_version_ |
1721430892552912896 |